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Abstract
Priorities for NTD control programmes will shift over the next 10-20 years as the elimination phase reaches the
‘end game’ for some NTDs, and the recognition that the control of other NTDs is much more problematic. The
current goal of scaling up programmes based on preventive chemotherapy (PCT) will alter to sustaining NTD
prevention, through sensitive surveillance and rapid response to resurgence. A new suite of tools and
approaches will be required for both PCT and Intensive Disease Management (IDM) diseases in this timeframe to
enable disease endemic countries to:
1. Sensitively and sustainably survey NTD transmission and prevalence in order to identify and respond quickly
to resurgence.
2. Set relevant control targets based not only on epidemiological indicators but also entomological and ecological
metrics and use decision support technology to help meet those targets.
3. Implement verified and cost-effective tools to prevent transmission throughout the elimination phase.
Liverpool School of Tropical Medicine (LSTM) and partners propose to evaluate and implement existing tools from
other disease systems as well as new tools in the pipeline in order to support endemic country ownership in NTD
decision-making during the elimination phase and beyond.
Background
With increased financial support and international politi-
cal momentum, the goals for neglected tropical diseases
(NTDs) control and elimination are changing. Over the
next five years we can expect disease-appropriate scale
up of community mass drug administration, intensified
case detection and management and scaling up vector
control [1]. Research is underway to integrate NTDs into
the health system, deliver care to neglected communities
and to optimize testing and treatment regimes. Improve-
ments in delivery and increased access will enable coun-
try programmes to meet their targets [2] and over the
next ten years we expect many countries to have success-
fully reached the WHO Roadmap objectives and the
London 2020 goals for the eliminable and eradicable
NTDs [1,3] and enter the “endgame”, i.e. the final stages
of elimination campaigns where disease is still present at
reduced levels [4]. During the endgame programme prio-
rities will shift from increasing intervention coverage in
order to meet elimination targets, to scaling down certain
interventions and sustaining elimination for the long
term through surveillance and targeted control.
Unique challenges facing control programmes
during the endgame
The elimination goals and timelines, as well as the control
approaches to reach these goals are as diverse as the 17
NTDs themselves. Lessons from malaria elimination
efforts have revealed heterogeneities in the stability of sus-
tained elimination due to a multitude of factors including
differences in transmission potential, reproductive rate,
cross border activity, socioeconomic status, baseline preva-
lence and human behaviour [5]. However, while it is
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impossible to draft a single elimination approach for one
disease, much less all NTDs, we can begin preparing for
the new and unique challenges likely to face NTD pro-
grammes in the endgame. The employment of existing,
community-wide strategies when prevalence is low will no
longer be cost-effective or epidemiologically justified and
instead we must prepare for the challenge of sustaining
surveillance and control following the anticipated post-
2020 scale down. Failure to reach elimination thresholds
during the endgame will compromise neighbouring and
regional NTD elimination; however what constitutes elim-
ination is poorly defined and elimination targets remain
untested.
Emerging priorities for control programmes
As country programmes move towards the 2020 mile-
stones and targets, they will require a new suite of tools
and approaches in order to sensitively assess transmis-
sion intensity and provide an evidence base for the
appropriate stage to cease community wide treatments
[6]. The tools and approaches that will lead to success
in meeting 2020 targets are not necessarily suitable for
the endgame. Successful and sustainable elimination will
hinge on a country programme’s ability to 1) identify
transmission and transmission risks; 2) decide how,
when and where to respond and 3) deliver optimum
interventions.
What LSTM can deliver
LSTM, in collaboration with many international part-
ners, has played a pivotal role in research to inform
NTD control; from the development and evaluation of
new tools for elimination, mapping and surveillance to
implementation research, capacity building and technical
assistance. We are well poised to deliver research on
how best to support country programmes through the
next phase by readying the tools, technologies and
approaches needed in response to the above emerging
needs. Specifically we propose to support elimination
programmes in surveillance, decision making and trans-
mission prevention (Fig 1).
Surveillance
Improved diagnostics and approaches to disease
surveillance
As we strive and reach for elimination in NTDs the
diagnostic requirements will change and there will be an
increased need for disease surveillance, identification of
foci and collection of data to inform decision making.
LSTM’s Research Centre for Drugs and Diagnostics
(RCDD) is working with industry (SMEs and larger
organisations), academia and other NGOs to discover,
develop and deliver novel drugs and diagnostics against
major human pathogens to meet these needs.
We anticipate that the PCT diseases will require large-
scale mapping and screening of patients in order to
identify hotspots of disease. It is essential that surveil-
lance is integrated into existing health system structures
in order that sustained monitoring can take place.
LSTM is working on molecular diagnostic surveillance
systems that will work hand-in-hand with existing net-
works such as the Global Polio Eradication Initiative
and Malaria Elimination Initiative.
The IDM NTDs such as HAT, leishmaniasis and den-
gue will require sensitive diagnostics that are able to pick
up asymptomatic and early infection, identify drug resis-
tance, monitor patient response and inform patient care.
Snakebite is an additional IDM NTD with specific chal-
lenges that include improved diagnostics as a tool for
both clinical management and assessing disease burden.
To enable decentralisation, testing devices should be por-
table and require only moderately invasive sampling
methodologies. LSTM are developing and/or evaluating
diagnostics such as LAMP, GeneXpert, Genedrive for use
in elimination settings. In the medium to long-term
RCDD will push for innovative diagnostic solutions that
will be close to the patient to inform treatment, patient
care and the ability to store data and transmit immedi-
ately to inform disease management tools.
Tools to monitor intervention efficacy and resistance
With insecticides playing an increasingly important role
in the elimination of vector-borne NTDs [1,6], it has
become necessary to monitor the emergence and spread
of insecticide resistance. LSTM has led the field in evalu-
ating intervention efficacy of insecticides for vector-
borne diseases and insecticide resistance detection and
management [7-9]. A range of new tools are becoming
available over the next two years which we will evaluate
for NTD vector control operations. Such tools include
new field-friendly assays to track the actual amounts of
insecticides being sprayed or used in nets, as well as new
methods to track the genes involved in resistance [10].
Integrating these into appropriate NTD vector control
operations could have game changing potential in pre-
venting transmission through effective use of insecticides
and tight monitoring of resistance.
For instance, the Insecticide Quantification Kits (IQK),
which are simple low cost assays that can be used on-site
to measure insecticides used for house spraying and bed-
nets, are now commercially available for carbamate and
cyanopyrethroid monitoring. Kits for DDT and organo-
phosphate monitoring are expected to be available in
2015. These kits will allow for internal validation of insec-
ticide-based control and enable programmes to optimize
the impacts of available tools. The IQK is currently being
adapted for the VL elimination programme in India, and
we propose further adapting it for monitoring Chagas and
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dengue programmes. Vector population monitoring tools
have been developed for malaria mosquitoes to identify
mosquito species, malaria infection status and resistance
mutations. This information is a key part of the data
needed by programme managers to evaluate transmission
impacts and mitigate potential resistance. The genomic
data accruing on NTD vectors can be readily exploited to
develop DNA based vector monitoring tools that parallel
those now being routinely applied for monitoring malaria
vectors.
Finally, a new generation of generic ‘predictive probes’
that are capable of identifying genes with insecticide
resistance potential have been recently developed [11].
These allow the development of ultra-early warning sys-
tems to detect incipient resistance at a point that some-
thing sensible can be done to prevent its spread.
We intend to translate these into practical insecticide
resistance monitoring tools across the spectrum of NTD
vectors. The availability of tools to monitor the impact of
interventions within the programme will allow for a rapid
adjustment in either the elimination tool or approach in
order to reach programme targets.
Decision support
Mapping to prioritize surveillance and coverage
Mapping prevalence data and the impact of single or
multiple interventions over time and space is critically
important to improve decision making for NTD pro-
grammes. We have developed novel mapping methods to
address the co-endemicity and overlapping interventions
to help determine the risks and benefits of different inter-
vention and surveillance strategies. The first we designate
as micro-stratification overlap mapping (MOM) which
focuses on the overlapping distribution of infections or
co-endemicity in a particular geographical area at a finer
spatial resolution. The MOM approach is essential for
planning the expanded distribution of drugs in countries
co-endemic for filarial infections, as has been demon-
strated in the Democratic Republic of Congo (DRC) and
Nigeria [12,13]. The second mapping method focuses on
quantifying the overlap and potential impact of multiple
interventions at subnational level to produce a multiple
intervention score map (MISM) [14]. The MISM
approach aims to develop practical programmatic maps
to assist NTD programme managers to identify and tar-
get high-risk areas that may not have received adequate
impacting interventions to interrupt the transmission of
the disease. This is critical for countries as they prepare
to scale down coverage and enter the elimination phase
as exemplified by the LF Elimination Programme in
Malawi [14]. In addition, geo-spatial models have been
developed to produce baseline risk maps, incorporating
socio-demographic and environmental factors, with the
aim of overlaying intervention coverage and predicting
areas where transmission is mostly likely to persist and
in need of alternative or enhanced intervention strate-
gies [15].
Disease Data Management Systems (DDMS)
Underpinning the successful elimination of NTDs will be
access to information. Masses of information on disease,
interventions, and vectors are being collected by control
programmes but are not mined to improve decision-
making. Countries will require tools that allow 1) easy
access to a central data repository and 2) interpretation
of that data to guide decisions on how to achieve the
greatest impact with limited resources. Informed deci-
sion-making will also allow programmes to identify prior-
ity areas for surveillance as well as when and where to
implement further control measures.
Figure 1 Proposed research outputs to directly support NTD programmes in sustaining elimination
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LSTM, with support from the Innovative Vector Control
Consortium (IVCC), has been instrumental in developing
and implementing a sophisticated Disease Data Manage-
ment System (DDMS) in endemic countries. At its core,
the DDMS is an open-source database for controlling pro-
gramme data, from case surveillance to entomological
monitoring to intervention data. However, there are
several features that make the system unique. First, it is
integrated with mapping and reporting tools, allowing pro-
grammes to use their data to support real-time informed
decision-making. Second, it has customizable thresholds
that will send alerts when targets are not being met. Third,
it is flexible enough to switch between several vector
borne diseases. Current modules include dengue, malaria
and most recently visceral leishmaniasis (VL).
Malaria modules have been implemented in Zambia,
Ethiopia, and Equatorial Guinea. The Zambian National
Malaria Control Centre and Zambia Integrated Systems
Strengthening Program have worked closely together to
use the system to monitor entomology and intervention
data with technical support from LSTM. Work is under-
way to integrate the DDMS with VL elimination efforts
in Bihar, India, enabling the country to track insecticide
resistance patterns, IRS coverage and quality, and case
surveillance data. Over the next 10-20 years, programmes
will transition from control to elimination, involving a
scale down from community-level to targeted interven-
tions. The DDMS is poised to facilitate this transition
and will be further developed to ensure that programmes
have access to critical information that support decision-
making.
Entomological and epidemiological research to validate
transmission endpoints for NTD elimination
Elimination targets remain untested and many pro-
grammes assume that a certain number of treatments or
a given number of MDA rounds will be sufficient to
interrupt transmission [6] of PCT diseases. Current
assumptions of threshold biting rates, and threshold
parasite breakpoints, below which transmission cannot
be sustained, are largely untested. It is essential that these
assumptions are validated to ensure elimination targets
are locally relevant.
For example, our research on vector-borne NTD trans-
mission has shown that differences in vector competence
are likely to influence elimination success [16]. Further
work, in collaboration with the NTD modelling group,
will refine transmission thresholds. Research to validate
elimination targets will involve experimental vector work
to determine transmission potential, modelling to predict
threshold inoculation rates sufficient for resurgence [17],
followed by observational studies throughout the elimi-
nation phase. With sufficient evidence, the DDMS can be
programmed to include updated, relevant and realistic
elimination targets. This will allow programmes to priori-
tize resources and gain confidence that intervention
efforts will be successful.
Tools to prevent transmission
Evaluate existing tools and their application to NTDs
Vector control is a fundamental element of the global
strategy to fight malaria, with a proven track record of
successfully reducing disease transmission. Indoor resi-
dual spraying (IRS) and long-lasting insecticidal nets
(LLINs) are the two core malaria vector control measures
broadly applicable to indoor biting vectors. Given their
success in malaria operations they are strongly recom-
mended for integration in NTD programmes with appro-
priate vectors (e.g. LF, VL, Chagas) [18]. Bednets have a
proven role in reducing snakebite incidence [19] and this
additional health benefit could be readily implemented
into integrated NTD management. Other vector-borne
NTDs (HAT, dengue, onchocerciasis, LF in Pacific) are
more difficult to integrate with existing programmes
because the vectors require different approaches that are
not currently used at scale. Existing vector-based inter-
ventions are proven to impact the vector population and
some recent studies have demonstrated direct impacts on
disease prevalence [20]. However, evidence is lacking to
date on the direct impact of vector control on the preva-
lence of many NTDs and the longer term contribution to
elimination.
Before recommending that available interventions be
tailored to and adopted by NTD programmes, we pro-
pose to critically evaluate their impact on NTD trans-
mission and prevalence. For many of the NTDs (e.g.
with longer periods of latency), this will require
extended periods of surveillance to ensure that vector
population reductions closely correspond with decreases
in incidence over time. We will build on our current
expertise in vector control for NTDs [21-25] and work
with our partners to strengthen the evidence base of the
available tools for NTD control.
Ability to evaluate suitability of new tools in the pipeline
for use in NTDs
A thorough evaluation of available and emerging che-
motherapies, diagnostics and vector control tools, map-
ping and decision making systems will allow programmes
to decide which interventions are likely to give the
desired impact, while also providing additional tools at
the ready if efficacy is compromised.
New chemotherapies are emerging for onchocerciasis,
LF and HAT [26-28] which will play an integral role in
case detection and treatment through the endgame. The
Anti-Wolbachia Consortium (A·WOL; http://www.a-wol.
com), a drug discovery and development programme [29],
was founded at LSTM in 2007 to screen, identify and
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validate novel drugs as well as develop treatment regimens
with existing macrofilaricidal drugs, e.g. doxycycline,
which has been adopted for use by elimination pro-
grammes as an alternative strategy in areas of Loa loa
co-endemicity and at risk of severe adverse events (SAE)
to ivermectin [26]. The benefits of an anti-Wolbachia
macrofilaricidal drug would be to 1) reduce programme
time frames, 2) provide an alternative treatment to existing
drugs with reduced efficacy, 3) be useable in Loa loa co-
endemic areas without risk of SAE, 4) improve morbidity
management, and 5) complement existing strategies for
MDA end-game.
In addition to the A·WOL approach to macrofilarici-
dal drug development, other strategies aim to discover
and develop macrofilaricidal drugs which act by directly
killing adult worms [27] with other candidates emerging
from the drug discovery pipeline. We propose to further
evaluate the suitability of emerging drugs for use in the
endgame and in areas where existing strategies are
compromised.
Diagnostic evaluation in well-designed trials is essen-
tial prior to and during implementation as prevalence
and endemic settings change. LSTM has several multi-
disease diagnostic evaluation sites including Nigeria,
Ethiopia and Malawi where the suitability of tests can
be appraised. Our Clinical Sciences unit is highly skilled
and qualified in the implementation of diagnostics and
their continued evaluation, suitability, cost-effectiveness
and roll-out.
The IVCC, established at LSTM in 2005, seeks to
overcome the barriers to innovation in the development
of vector control tools. It is supporting the development
of novel insecticides, long-lasting formulations, and
delivery mechanisms that will improve the efficacy of
chemical control. Currently, there are eight novel classes
of chemistry under evaluation, and three new active
ingredients will be brought to market to act as alterna-
tives to pyrethroids and other chemical classes that are
now showing resistance. Improvements in the residuality
of indoor residual sprays via new products such as
Bayer’s new polymer-enhanced formulation of deltame-
thrin and Syngenta’s primiphos-methyl CS formulation
have been rolled out, and combination nets that incor-
porate synergists or multiple insecticides are being eval-
uated to overcome pyrethroid resistance [10].
Conclusion
The shift in priorities and the emergence of new chal-
lenges as national NTD programmes approach the end-
game will require a new suite of tools and approaches to
sustain elimination. Many tools for surveillance, decision
making and long term transmission prevention are in the
pipeline or are currently being successfully applied in
other disease control programmes. We must prioritise
the evaluation, application and implementation of these
tools in order to support NTD programmes in reaching
and sustaining their elimination targets.
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